Local Treatment of Recurrent Renal Cell Carcinoma May Have a Significant Survival Effect Across All Risk-of-recurrence Groups.

Retrospective comparative studies suggest a survival benefit after complete local treatment of recurrence (LTR) in renal cell carcinoma (RCC), which may be largely due to an indication bias.

To determine the role of LTR in a homogeneous population characterised by limited and potentially resectable recurrence.

RECUR is a protocol-based multicentre European registry capturing patient and tumour characteristics, risk of recurrence (RoR), recurrence patterns, and survival of those curatively treated for nonmetastatic RCC from 2006 to 2011. Per-protocol resectable disease (RD) recurrence was defined as (1) solitary metastases, (2) oligometastases, or (3) renal fossa or renal recurrence after radical or partial nephrectomy, respectively.

Local treatment of recurrence.

Overall survival (OS) and cancer-specific survival was compared in the RD population that underwent LTR versus no LTR. We constructed a multivariate model to predict risk factors for overall mortality and analysed the effect of LTR across RoR groups.

Of 3039 patients with localised RCC treated with curative intent, 505 presented with recurrence, including 176 with RD. Of these patients, 97 underwent LTR and 79 no LTR. Patients in the LTR group were younger (64.3 [40-80] vs 69.2 [45-87] yr; p = 0.001). The median OS was 70.3 mo (95% confidence interval [CI] 58-82.6) versus 27.4 mo (95% CI 23.6-31.15) in the LTR versus no-LTR group (p < 0.001). After a multivariate analysis, having LTR (hazard ratio [HR] 0.37 [95% CI 0.2-0.6]), having low- versus high-risk RoR (HR 0.42 [95% CI [0.20-0.83]), and not having extra-abdominal/thoracic metastasis (HR 1.96 [95% CI 1.02-3.77]) were prognostic factors of longer OS. The LTR effect on survival was consistent across risk groups. OS HR for high, intermediate, and low risks were 0.36 (0.2-0.64), 0.27 (0.11-0.65), and 0.26 (0.08-0.8), respectively. Limitations include retrospective design.

This is the first study assessing the effectiveness of LTR in RCC in a comparable population with RD. This study supports the role of LTR across all RoR groups.

We assessed the effectiveness of local treatment of resectable recurrent renal cell carcinoma after surgical treatment of the primary kidney tumour. Local treatment of recurrence was associated with longer survival across groups with a risk of recurrence.

European urology open science. 2022 Dec 15*** epublish ***

Lorenzo Marconi, Teele Kuusk, Umberto Capitanio, Christian Beisland, Thomas Lam, Sergio Fernandez Pello, Grant D Stewart, Tobias Klatte, Alessandro Volpe, Borje Ljungberg, Saeed Dabestani, Axel Bex

Department of Urology and Renal Transplantation, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal., Royal London Hospital, Barts Health NHS Trust, London, UK., Department of Urology, San Raffaele Scientific Institute, Milan, Italy., Department of Clinical Medicine, University of Bergen, Bergen, Norway., Academic Urology Unit, University of Aberdeen, Aberdeen, UK., Department of Urology, Cabueñes University Hospital, Gijón, Spain., Department of Surgery, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK., Department of Urology, Charité Universitaetsmedizin Berlin, Berlin, Germany., Department of Urology, University of Eastern Piedmont, Maggiore della Carità Hospital, Novara, Italy., Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden., Department of Translational Medicine, Division of Urological Cancers, Lund University, Malmö, Sweden., Department of Urology, The Royal Free London NHS Foundation Trust, London, UK.